The cell surface markers market is projected to reach USD 769 million by 2023 from USD 520 million in 2018, at a CAGR of 8.1% during the forecast period. The growth of this market is majorly driven by the increasing funding for life sciences research, high global prevalence of cancer, and growth in stem cell and neurobiology research.
The cell surface markers market is highly fragmented in nature, with several big as well as emerging players vying for market shares. Prominent players in this market include Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (US), F. Hoffman-La Roche (Switzerland), Bio-Rad Laboratories (US), Danaher Corporation (US), Abcam (UK), GenScript (China), BioLegend (US), Cell Signaling Technology (US), Merck KGaA (Germany), and Bio-Techne (US). These players have adopted various strategies, such as partnerships, agreements, collaborations, and product launches to further expand their presence in the global cell surface markers market. Partnerships, collaborations, and agreements have been the key growth strategies adopted from 2016 to 2018, by players such as Abcam, GenScript, and QIAGEN N.V.
To know about the assumptions considered for the study download the pdf brochure
Thermo Fisher Scientific is one of the leading players in the cell surface markers market. The company’s strong brand recognition and extensive product portfolio is its key strength. In order to maintain its leading position in this market, Thermo Fisher adopts organic and inorganic growth strategies such as acquisitions and expansions. For instance, in the last three years, the company acquired Affymetrix (US) and the Advanced Bioprocessing business from Becton, Dickinson and Company (US). Such acquisitions help Thermo Fisher in strengthening its Life Sciences Solutions segment for versatile product offerings. The company’s efforts towards enhancing its financial strategies have also significantly helped in sustaining its existing position within this market.
Becton, Dickinson and Company (BD) is one of the prominent players in the cell surface markers market. BD offers a robust product portfolio and has a strong geographical presence in this market. Its products are marketed internationally and in the US through independent distribution channels; they are also marketed directly to end users by the company itself, and also by independent sales representatives. The primary end users of the company’s products are hospitals, laboratories and clinics, blood banks, healthcare workers, public health agencies, academic and government institutions, and pharmaceutical and biotechnology companies.
Cell Surface Markers Market by Product (Antibody, PCR Array), Source (Mice, Rat), Cell Type (T cells, B cells, NK cell), Application (Research (Stem Cell, Immunology), Clinical (Oncology, Hematology)), and End User (Hospitals) - Global Forecast to 2023
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE